Clinical Trial Update: Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating combinations of ivosidenib and venetoclax with or without azacitidine in IDH1-mutated hematologic malignancies, including …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myeloproliferative Neoplasm

Drugs mentioned

• Tibsovo (ivosidenib)
• VIDAZA (AZACITIDINE)
• Venclexta (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia, Hematopoietic and Lymphoid System Neoplasm | Phase 1, Phase 2 | Status: RECRUITING